Savant Capital LLC Sells 276 Shares of Amgen, Inc. (NASDAQ:AMGN)

Savant Capital LLC trimmed its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 5.0% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 5,205 shares of the medical research company’s stock after selling 276 shares during the quarter. Savant Capital LLC’s holdings in Amgen were worth $959,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in AMGN. Bangor Savings Bank raised its position in Amgen by 2.1% in the first quarter. Bangor Savings Bank now owns 2,682 shares of the medical research company’s stock valued at $510,000 after purchasing an additional 55 shares during the last quarter. Carroll Financial Associates Inc. raised its position in Amgen by 0.8% in the second quarter. Carroll Financial Associates Inc. now owns 7,436 shares of the medical research company’s stock valued at $1,370,000 after purchasing an additional 58 shares during the last quarter. Lincoln Capital Corp raised its position in Amgen by 0.3% in the second quarter. Lincoln Capital Corp now owns 21,483 shares of the medical research company’s stock valued at $3,959,000 after purchasing an additional 58 shares during the last quarter. Slow Capital Inc. raised its position in Amgen by 0.4% in the second quarter. Slow Capital Inc. now owns 13,799 shares of the medical research company’s stock valued at $2,543,000 after purchasing an additional 58 shares during the last quarter. Finally, CWM LLC raised its position in Amgen by 1.8% in the second quarter. CWM LLC now owns 3,271 shares of the medical research company’s stock valued at $603,000 after purchasing an additional 59 shares during the last quarter. Hedge funds and other institutional investors own 78.01% of the company’s stock.

In related news, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $175.68, for a total transaction of $351,360.00. Following the completion of the sale, the director now owns 16,219 shares of the company’s stock, valued at $2,849,353.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total value of $77,792.00. Following the sale, the director now directly owns 16,336 shares of the company’s stock, valued at approximately $2,990,141.44. The disclosure for this sale can be found here. Insiders have sold 4,425 shares of company stock valued at $804,312 in the last ninety days. 0.25% of the stock is currently owned by insiders.



Several equities research analysts have recently weighed in on AMGN shares. Royal Bank of Canada increased their price target on Amgen to $192.00 and gave the company a “sector perform” rating in a research note on Wednesday. JPMorgan Chase & Co. reissued a “hold” rating on shares of Amgen in a research note on Friday, August 9th. BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Credit Suisse Group reissued an “outperform” rating and issued a $225.00 price target (up previously from $202.00) on shares of Amgen in a research note on Friday, August 16th. Finally, Citigroup reissued a “buy” rating on shares of Amgen in a research note on Monday, August 12th. Ten investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Amgen has an average rating of “Buy” and a consensus target price of $212.94.

NASDAQ AMGN traded down $4.34 during trading hours on Friday, hitting $199.08. 2,734,319 shares of the company’s stock were exchanged, compared to its average volume of 3,927,736. The stock has a 50-day simple moving average of $186.41 and a 200 day simple moving average of $183.47. Amgen, Inc. has a 1-year low of $166.30 and a 1-year high of $211.90. The firm has a market cap of $122.30 billion, a price-to-earnings ratio of 13.83, a PEG ratio of 2.46 and a beta of 1.19. The company has a current ratio of 2.89, a quick ratio of 2.60 and a debt-to-equity ratio of 2.58.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, topping the consensus estimate of $3.58 by $0.39. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The business had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter last year, the firm posted $3.83 earnings per share. The firm’s revenue was down 3.1% on a year-over-year basis. On average, sell-side analysts anticipate that Amgen, Inc. will post 14.26 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 6th. Investors of record on Thursday, August 15th will be paid a dividend of $1.45 per share. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $5.80 annualized dividend and a yield of 2.91%. Amgen’s dividend payout ratio is currently 40.28%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: What is a CD ladder?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.